Full Press Release Details
Expands Global Market Footprint to Spearhead Medical Innovation with MoUs in Indonesia
to drive clinical research, enhance product safety, and combat respiratory diseases
LUMPUR, 29 NOVEMBER 2024 - NASDAQ-listed AGAPE ATP Corporation ("ATPC"), today announced the signing
of three Memorandums of Understanding ("MOUs") with prominent healthcare institutions in Indonesia. This initiative aims
to advance medical research, introduce innovative treatment strategies and strengthen training programs to address respiratory diseases
such as tuberculosis (TB) and chronic obstructive pulmonary disease (COPD). The signing marks a key milestone in ATPC's strategic
expansion plans in Indonesia and Southeast Asia.
MoUs were signed with Dr. Sardjito General Hospital in Yogyakarta, Dr. H. A. Rotinsulu Lung Hospital in Bandung,
and Dr. M. Goenawan Partowidigdo Respiratory Hospital in Bogor. These partnerships focus on enhancing research capabilities,
fostering medical innovations, and conducting clinical studies on ATPC's existing health products. These studies ensure the products
comply with Indonesian health standards for safe consumption and use, meeting regulatory requirements prior to market distribution of
these partnerships, ATPC reaffirms its commitment to maintaining the highest standards of safety and efficacy for its health products,
further solidifying its position as a trusted innovator in the healthcare industry.
collaborations are built on a shared vision to address critical global health challenges. Together, the parties aim to foster interdisciplinary
collaboration, knowledge exchange, and sustainable health practices. Key initiatives include advanced medical research, healthcare professional
training, and the introduction of innovative approaches to combat respiratory diseases. The partnerships also aim to connect with international
universities and specialist hospitals to further elevate healthcare standards.
Dato' Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC said, "TB and COPD remain major public health concerns
in both Indonesia and Malaysia. Indonesia ranks among the countries with the highest TB burden globally, with hundreds of thousands of
new cases reported annually. Meanwhile, COPD, often linked to high rates of smoking and air pollution, significantly contributes to illness
and mortality in both nations. These diseases place immense strain on healthcare systems, highlighting the urgent need for collaborative
efforts to improve prevention, diagnosis, and treatment strategies."
partnerships also emphasize the integration of sustainable medical innovations, aiming to enhance long-term well-being and align with
the United Nations Sustainable Development Goals ("UNSDG"). Through these collaborations, ATPC reinforces its role
as a global leader in wellness and healthcare, advancing scientific research and sustainable health outcomes.
MoU signing ceremony was graced by distinguished guests from the Indonesian Ministry of Health, including Dr. Suranto M.Kes, Director
of Health Service Governance, and Prof. Dr. Taruna Ikrar, Head of the Food and Drug Supervisory Authority (BPOM), an agency under
the Ministry of Health. Also present were representatives from ATPC, including Prof. Dato' Sri Dr. How Kok Choong, Founder
and Group CEO; Dr. John Vong, Deputy Chairman; and Dr. Fernando Cortizo, Executive Director.
AGAPE ATP Corporation
ATP Corporation (ATPC) is dedicated to enhancing the quality of life and promoting sustainable development. With a strong foundation
built on two core business pillars, ATPC specialises in the provision of health and wellness products that caters to the diverse needs
of its customers, ensuring their well-being and vitality. Additionally, APTC delivers comprehensive energy-saving solutions that empower
companies to drive sustainability initiatives, reduce energy consumption, and achieve their sustainability goals.
more information, visit www.agapeatpgroup.com.
By: Koa International Sdn. Bhd. on behalf of Agape ATP Corporation
more information, please contact:
statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected benefits and outcomes
of the partnerships announced by AGAPE ATP Corporation ("ATPC") and the potential for medical innovations and healthcare
advancements through these collaborations. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would," and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking
statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially
from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and
risks including, but not limited to, the Company's ability to execute its strategies, manage growth, and maintain its corporate
culture; the Company's future business development, financial conditions, and results of operations; expectations regarding demand
for and market acceptance of our products and services; changes in technology; economic conditions; reputation and brand; the impact
of competition and pricing; government regulations; fluctuations in general economic and business conditions in Malaysia and the international
markets the Company plans to serve, and assumptions underlying or related to any of the foregoing and other risks contained in reports
filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking
statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and
AGAPE ATP Corporation specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.